The Increasing Hepatitis, Obesity Coupled With Other Chronic Liver Disease Has Enriched The Growth of the Global Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market

The global NASH biomarkers market is anticipated to grow significantly at a CAGR of 28.6% during the forecast period. The growing number of hepatitis with obesity and other chronic liver disease is growing the global Non-alcoholic Steatohepatitis Biomarkers market. Hepatitis is an inflammation of the liver that is caused by a variety of infectious viruses and noninfectious agents leading to a range of health problems. Factors such as hepatitis and obesity have contributed to the diagnosis and treatment market, as the number of patients increases the need for these Non-alcoholic Steatohepatitis Biomarkers increases. According to WHO, 354 million peoples across the globe live with hepatitis B or C. 

• Globally, an estimated 58 million people have chronic hepatitis C virus infection, with about 1.5 million new infections occurring per year.
• WHO estimated that in 2019, approximately 290 000 people died from hepatitis C, mostly from cirrhosis and hepatocellular carcinoma (primary liver cancer).

According to a WHO study around 4.5 million premature deaths could be prohibited in low- and middle-income countries by 2030 through vaccination, diagnostic tests, medicines, and education campaigns, which further contribute to the growth of the global Non-alcoholic Steatohepatitis Biomarkers market. In addition, Obesity and chronic liver disease patients fuelling the market. For instance according to CDC, in the US  the number of adults with diagnosed liver disease is around 4.5 million with 51,642 deaths. Hence diagnosis and treatment are vastly needed which is increasing the market.

Browse the full report description “Global Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Size, Share & Trends Analysis Report by Biomarker Type (Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers, and Others), and by End-Users (Hospitals, Diagnostic Laboratories, Academic Research Institute, and Pharmaceutical Companies/CRO) Forecast Period (2022-2028)” at https://www.omrglobal.com/industry-reports/non-alcoholic-steatohepatitis-biomarkers-market 

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028

Segment Covered-

• By Biomarker Type
• By End-Users

Regions Covered-

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape- Allergan PLC, Bristol-Myers Squibb Co., Gilead Sciences, Inc., Siemens Healthcare Medical Solutions Ltd., and Thermo Fisher Scientific, Inc., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment/region dominates the market in the base year?
• Which segment/region will project the fastest growth in the market?
• How has COVID-19 impacted the market?

oRecovery Timeline

oDeviation from the pre-COVID forecast

oMost affected region/segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Segmentation

By Biomarker Type

• Serum Biomarkers
• Hepatic Fibrosis Biomarkers
• Apoptosis Biomarkers
• Oxidative Stress Biomarkers
• Others (Carbon Isotope Markers and miRNA Biomarkers)

By End-Users 

• Hospitals
• Diagnostic Laboratories
• Academic Research Institute
• Pharmaceutical Companies/CRO

Global Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market by Region 

North America           

• US
• Canada

Europe

• Germany
• United Kingdom
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific    

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Middle East & Africa 
• Latin America 

To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/non-alcoholic-steatohepatitis-biomarkers-market